P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA

Bibliographic Details
Main Authors:	Nicolas Thomas Iannozzi, Jessica Burroughs Garcia, Paola Storti, Denise Toscani, Valentina Marchica, Valentina Franceschi, Luca Agnelli, Vincenzo Raimondi, Giannalisa Todaro, Oxana Lungu, Matia Bernardi, Gabriella Sammarelli, Gaetano Donofrio, Benedetta Dalla Palma, Nicola Giuliani
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970224.82329.18

Similar Items

Identification of <i>PSMB4</i> and <i>PSMD4</i> as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma
by: Jessica Burroughs Garcia, et al.
Published: (2023-08-01)

The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged
by: Paola Storti, et al.
Published: (2019-10-01)

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets
by: Jessica Burroughs Garcìa, et al.
Published: (2021-06-01)

CD38 expression by plasma cells in extramedullary multiple myeloma
by: Laura Notarfranchi, et al.
Published: (2023-11-01)

P850: THE HUMORAL AND CELLULAR RESPONSE TO SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA AND PRE-MALIGNANT MONOCLONAL GAMMOPATHIES: IMPACT OF OMICRON VARIANT
by: P. Storti, et al.
Published: (2022-06-01)

Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients
by: Vincenzo Raimondi, et al.
Published: (2025-02-01)

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
by: L. Notarfranchi, et al.
Published: (2023-05-01)

SMOLDERING MULTIPLE MYELOMA IN LATIN AMERICA
by: EQ Crusoe, et al.
Published: (2024-10-01)

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts
by: Marina Bolzoni, et al.
Published: (2017-04-01)

Genomic patterns of progression in smoldering multiple myeloma
by: Bolli, N, et al.
Published: (2018)

Systemic Mastocytosis Associated with “Smoldering” Multiple Myeloma
by: Magda Zanelli, et al.
Published: (2021-01-01)

Risk Stratification and Treatment in Smoldering Multiple Myeloma
by: Tyler Lussier, et al.
Published: (2021-12-01)

Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients
by: Vincenzo Raimondi, et al.
Published: (2024-10-01)

Genomic analysis of high-risk smoldering multiple myeloma
by: Lucía López-Corral, et al.
Published: (2012-09-01)

Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case
by: Sassine Ghanem, et al.
Published: (2016-01-01)

Identification of clinical‐biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation
by: Lorenzo Cillo, et al.
Published: (2024-08-01)

High rate of progression to symptomatic multiple myeloma in patients with smoldering myeloma and isolated osteoporotic vertebral fracture
by: Kevin Chevalier, et al.
Published: (2024-06-01)

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells
by: Paola Storti, et al.
Published: (2016-03-01)

Analysis of smoldering multiple myeloma according to the target of the monoclonal immunoglobulin of patients
by: Sylvie Hermouet, et al.
Published: (2024-12-01)

Mode of progression in smoldering multiple myeloma: a study of 406 patients
by: Nadine H. Abdallah, et al.
Published: (2024-01-01)

Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma
by: Annika Werly, et al.
Published: (2024-10-01)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Elena Zamagni, et al.
Published: (2020-12-01)

Upper Gastrointestinal Bleeding from Gastric Amyloidosis in a Patient with Smoldering Multiple Myeloma
by: Mihajlo Gjeorgjievski, et al.
Published: (2015-01-01)

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis
by: Elisabet E. Manasanch, et al.
Published: (2019-08-01)

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
by: Sham Mailankody, et al.
Published: (2017-10-01)

Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML
by: Bita Fakhri, et al.
Published: (2017-01-01)

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials
by: Elisabet E Manasanch, et al.
Published: (2014-12-01)

Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma
by: George Mellgard, et al.
Published: (2024-03-01)

Clinician preferences on treatment of smoldering myeloma: a cross-sectional surveyResearch in context
by: Ghulam Rehman Mohyuddin, et al.
Published: (2023-11-01)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
by: Pellegrino Musto, et al.
Published: (2021-07-01)

Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma
by: Natthakan Thongon, et al.
Published: (2024-02-01)

IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA?
by: Ugo Testa, et al.
Published: (2024-04-01)

Severe Pulmonary Hypertension Caused by Smoldering Plasma Cell Myeloma: An Autopsy Case of POEMS Syndrome
by: Katsuya Chinen, et al.
Published: (2012-01-01)

Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions
by: Valeria Ferla, et al.
Published: (2024-07-01)

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
by: Rashid Khan, et al.
Published: (2015-09-01)

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
by: Sonia Morè, et al.
Published: (2025-01-01)

Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling
by: Vernon Wu, et al.
Published: (2018-06-01)

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
by: Neha Korde, et al.
Published: (2014-06-01)

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
by: Anna deDaniel, et al.
Published: (2024-05-01)

PB2077: COMPARISON OF PLASMA CELL PERCENTAGE BY BONE MARROW ASPIRATE MORPHOLOGY AND CD138-STAINED BONE MARROW BIOPSY IN SMOLDERING MYELOMA TO PREDICT TRANSFORMATION TO SYMPTOMATIC MYELOMA
by: Helen Cashman, et al.
Published: (2023-08-01)